UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)

x	~~QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934~~

x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~September 30,~~December 31, 2011

o	~~TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT~~

o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

For the transition period from __________ to __________

Commission file number 001-31392

PLURISTEM THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

Nevada		98-0351734
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)

MATAM Advanced Technology Park, Building No. 20, Haifa, Israel 31905

(Address of principal executive offices)

+972-74-710-7171

(Registrant’s telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registration was required to submit and post such files).

Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer o	~~Accelerated filer~~ o
Non-accelerated filer o	~~Smaller reporting company~~ x
(Do not check if a smaller reporting company)		Accelerated filer o Smaller reporting company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes o No x

State the number of shares outstanding of each of the issuer’s classes of common stock as of the latest practicable date: ~~43,779,291common~~44,345,101common shares issued as of ~~November~~February 4, ~~2011.~~2012.

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

CONSOLIDATED FINANCIAL STATEMENTS

As of ~~September 30,~~December 31, 2011

(unaudited)

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

CONSOLIDATED FINANCIAL STATEMENTS

As of ~~September 30,~~December 31, 2011

U.S. DOLLARS IN THOUSANDS

(Unaudited)

INDEX

	Page

Consolidated Balance Sheets	F - 2-2 - F - 3

Consolidated Statements of Operations	F - 4

Statements of changes in ~~Stockholders’~~ Equity	F - 5 - F - 6

Consolidated Statements of Cash Flows	F - 7 - F - 8

Notes to Consolidated Financial Statements	F - 9 - F - 2019

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

CONSOLIDATED BALANCE SHSHEETS~~EETS~~

U.S. Dollars in thousands

September 30, 2011 June 30, 2011
Note Unaudited Audited
ASSETS

CURRENT ASSETS:

Cash and cash equivalents $ 13,633 $ 42,829
Short term bank deposits 31,658 -
Marketable securities 3 513 -
Prepaid expenses 334 314
Other accounts receivable 225 154
Total current assets
46,363 43,297

LONG-TERM ASSETS:

Long-term deposits and restricted deposits 866 179
Severance pay fund 459 452
Property and equipment, net 2,156 2,088
Total long-term assets
3,481 2,719

Total assets
$ 49,844 $ 46,016

		December 31, 2011		June 30, 2011
	Note	Unaudited		Audited
ASSETS

CURRENT ASSETS:

Cash and cash equivalents		$	6,672	$	42,829
Short term bank deposits			30,491		-
Marketable securities	3		4,352		-
Prepaid expenses			217		314
Accounts receivable from the Office of the Chief Scientist			1,845		-
Other accounts receivable			266		154
Total current assets			43,843		43,297

LONG-TERM ASSETS:

Long-term deposits and restricted deposits			1,186		179
Severance pay fund			485		452
Advance payment for leasehold improvements	6c		1,245		-
Property and equipment, net			2,883		2,088
Total long-term assets			5,799		2,719

Total assets		$	49,642	$	46,016

The accompanying notes are an integral part of the consolidated financial statements.

F - 2

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

CONSOLIDATED BALANCE SHEETS

U.S. Dollars in thousands

		September 30, 2011			June 30, 2011				December 31, 2011			June 30, 2011
	Note	Unaudited			Audited			Note	Unaudited			Audited
LIABILITIES AND STOCKHOLDERS’ EQUITY

CURRENT LIABILITIES

Trade payables		$	1,076		$	1,177			$	1,174		$	1,177
Accrued expenses			376			208				231			208
Deferred revenues			923			-				923			-
Advanced payment			2,000			-
Advance payment										1,926			-
Other accounts payable			670			633				722			633
Total current liabilities			5,045			2,018				4,976			2,018

LONG-TERM LIABILITIES

Deferred revenues			3,923			-				3,692			-
Accrued severance pay			582			576				622			576
Total long term liabilities			4,505			576				4,314			576

COMMITMENTS AND CONTINGENCIES	5							5

STOCKHOLDERS’ EQUITY

Share capital:	6							6
Common stock $0.00001 par value: Authorized: 100,000,000 shares Issued and outstanding: 42,985,243 shares as of September 30, 2011, 42,443,185 shares as of June 30, 2011.			- (*)			- (*)
Common stock $0.00001 par value:
Authorized: 100,000,000 shares Issued and outstanding: 44,117,044 shares as of December 31, 2011, 42,443,185 shares as of June 30, 2011										- (*	)		- (*	)
Additional paid-in capital			95,739			94,375				97,924			94,375
Accumulated deficit			(55,446	)		(50,953	)			(57,438	)		(50,953	)
Other comprehensive income			1			-
Other comprehensive loss										(134	)		-
			40,294			43,422				40,352			43,422

		$	49,844		$	46,016			$	49,642		$	46,016

~~(*)~~

~~Less than $1.~~

~~PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY~~

~~CONSOLIDATED STATEMENTS OF OPERATIONS~~

~~U.S. Dollars in thousands (except share and per share data)~~

~~The accompanying notes are an integral part of the consolidated financial statements.~~

~~F - 4~~

~~PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY~~

~~STATEMENTS OF CHANGES IN~~ ~~STOCKHOLDERS' EQUITY~~ ~~(AUDITED)~~

Issuance of common stock and warrants related to October

2010 agreements, net of issuance costs of $244

Issuance of common stock and warrants related to February

2011 secondary offering, net of issuance costs of $2,970

Stock based compensation to employees, directors and

non-employees consultants

The accompanying notes are an integral part of the consolidated financial statements.

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

CONSOLIDATED STATEMENTS OF OPERATIONS

U.S. Dollars in thousands (except share and per share data)

	Six months ended December 31,						Three months ended December 31,						Year ended June 30,
	2011			2010			2011			2010			2011
	Unaudited			Unaudited			Unaudited			Unaudited			Audited

Revenues	$	385		$	-		$	231		$	-		$	-

Research and development expenses		(5,844	)		(3,687	)		(2,976	)		(2,186	)		(8,311	)

Less participation by the Office of the Chief Scientist and other parties		1,921			1,111			1,902			608			1,682

Research and development expenses, net		(3,923	)		(2,576	)		(1,074	)		(1,578	)		(6,629	)

General and administrative expenses		(2,912	)		(2,002	)		(1,275	)		(1,246	)		(4,485	)

Operating loss		(6,450	)		(4,578	)		(2,118	)		(2,824	)		(11,114	)

Financial (expenses) income, net		(35	)		68			126			3			266

Net loss for the period	$	(6,485	)	$	(4,510	)	$	(1,992	)	$	(2,821	)	$	(10,848	)

Loss per share:

Basic and diluted net loss per share	$	(0.15	)	$	(0.20	)	$	(0.05	)	$	(0.11	)	$	(0.35	)

Weighted average number of shares used in computing basic and diluted net loss per share		43,225,017			22,954,736			43,669,466			24,897,022			31,198,825

The accompanying notes are an integral part of the consolidated financial statements.

F - 4

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

STATEMENTS OF CHANGES IN ~~STOCKHOLDERS'~~ EQUITY ~~(UNAUDITED)~~(AUDITED)

U.S. Dollars in thousands (except share and per share data)

Common Stock Additional Paid-in Accumulated Other Comprehensive Deficit Total Stockholders’

Shares

Amount

Capital

gain

Accumulated

Equity

Balance as of July 1, 2011 42,443,185 $ (*) $ 94,375 $ - $ (50,953 ) $ 43,422
Exercise of options by employees and consultants 12,500 (*) 8 - - 8
Exercise of warrants by investors and finders 198,714 (*) 315 - - 315
Stock based compensation to employees, directors
and non-employees consultants
330,844 (*) 1,041 - - 1,041
Unrealized gain on available for sale marketable securities - - - 1 - 1
Net loss for the period - - - - (4,493 ) (4,493 )
Balance as of September 30, 2011 42,985,243 $ (*) $ 95,739 $ 1 $ (55,446 ) $ 40,294

	Common Stock					Additional Paid-in		Accumulated			Total Stockholders’
	Shares		Amount			Capital		Deficit			Equity

Balance as of July 1, 2010		20,888,781	$	(*	)	$	44,086	$	(40,105	)	$	3,981

Issuance of common stock and warrants related to October 2010 agreements, net of issuance costs of $244		4,375,000		(*	)		5,006		-			5,006

Issuance of common stock and warrants related to February 2011 secondary offering, net of issuance costs of $2,970		12,650,000		(*	)		38,142		-			38,142

Exercise of warrants by investors and finders		2,442,714		(*	)		3,593		-			3,593

Exercise of options by employees and consultants		103,943		(*	)		68		-			68

Issuance of common stock related to investor relations agreements		90,000		(*	)		155		-			155

Stock based compensation to employees, directors and non-employees consultants		1,892,747		(*	)		3,325		-			3,325

Net loss for the period		-		-			-		(10,848	)		(10,848	)

Balance as of June 30, 2011		42,443,185	$	(*	)	$	94,375	$	(50,953	)	$	43,422

(*) Less than $1.

The accompanying notes are an integral part of the consolidated financial statements.

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

STATEMENTS OF CHANGES IN EQUITY (UNAUDITED)

U.S. Dollars in thousands (except share and per share data)

	Common Stock					Additional Paid-in		Accumulated Other Comprehensive			Deficit			Total Stockholders’
	Shares		Amount			Capital		Loss			Accumulated			Equity

Balance as of July 1, 2011		42,443,185	$	(*	)	$	94,375	$	-		$	(50,953	)	$	43,422

Exercise of options by employees and consultants		23,000		(*	)		14		-			-			14

Exercise of warrants by investors and finders		283,266		(*	)		371		-			-			371

Stock based compensation to employees, directors and non-employees consultants		1,367,593		(*	)		3,164		-			-			3,164

Unrealized loss on available for sale marketable securities		-		-			-		(134	)		-			(134	)

Net loss for the period		-		-			-		-			(6,485	)		(6,485	)

Balance as of December 31, 2011		44,117,044	$	(*	)	$	97,924	$	(134	)	$	(57,438	)	$	40,352

(*) Less than $1.

The accompanying notes are an integral part of the consolidated financial statements.

F - 6

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

CONSOLIDATED STATEMENTS OF CASH FLOWS

U.S. Dollars in thousands

	Six months ended December 31,						Year ended June 30,
	2011			2010			2011
	Unaudited			Unaudited			Audited
CASH FLOWS FROM OPERATING ACTIVITIES:

Net loss	$	(6,485	)	$	(4,510	)	$	(10,848	)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation		199			144			312
Capital loss		-			8			8
Impairment of property and equipment		-			-			11
Stock-based compensation to employees, directors and non-employees consultants		1,904			1,464			3,325
Stock compensation to investor relations consultants		-			78			155
Decrease (increase) in other accounts receivable		(1,960	)		317			656
Decrease (increase) in prepaid expenses		97			(15	)		(273	)
Increase (decrease) in trade payables		(1	)		254			455
Increase in other accounts payable and accrued expenses		112			34			375
Increase in deferred revenues		4,615			-			-
Increase in advance payment		1,926			-			-
Increase (Decrease) in interest receivable on short-term deposit		(240	)		15			15
Linkage differences and interest on short-term restricted lease deposit		22			-			-
Linkage differences and interest on long-term restricted lease deposit		5			(3	)		(4	)
Amortization of discount, premium and changes in accrued interest from marketable securities		(33	)		-			-
Accrued severance pay, net		13			(5	)		58
Net cash provided by operating activities	$	174		$	(2,219	)	$	(5,755	)

CASH FLOWS FROM INVESTING ACTIVITIES:

Purchase of property and equipment	$	(996	)	$	(560	)	$	(962	)
Investment in short-term deposits		(30,273	)		-			-
Proceeds from short-term deposits		-			898			898
Proceeds from sale of property and equipment		-			28			29
Investment in long-term deposits		(1,011	)		(12	)		(14	)
Repayment of long-term restricted deposit		2			13			13
Proceeds from sale of available for sale marketable securities		50			-			-
Purchase of available for sale marketable securities		(4,503	)		-			-
Net cash provided by (used in) investing activities	$	(36,731	)	$	367		$	(36	)

The accompanying notes are an integral part of the consolidated financial statements.

F - 7

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

CONSOLIDATED STATEMENTS OF CASH FLOWS

U.S. Dollars in thousands

Three months ended
September 30,

Year ended
June 30,

2011 2010 2011
Unaudited Unaudited Audited
CASH FLOWS FROM OPERATING ACTIVITIES:

Net loss $ (4,493 ) $ (1,689 ) $ (10,848 )

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation 97 70 312
Capital loss - 8 8
Impairment of property and equipment - - 11
Stock-based compensation to employees, directors and non-employees consultants 1,041 462 3,325
Stock compensation to investor relations consultants - 36 155
Decrease (increase) in other accounts receivable (76 ) 425 656
Decrease (increase) in prepaid expenses (20 ) (39 ) (273 )
Increase (decrease) in trade payables (87 ) 1 455
Increase in other accounts payable and  accrued expenses 205 33 375
Increase in deferred revenues 4,846 - -
Increase in advanced payment 2,000 - -
Increase in interest receivable on short-term deposit (74 ) (4 ) 15
Linkage differences and interest on short-term  restricted lease deposit 15 - -
Linkage differences and interest on long-term  restricted lease deposit 4 (1 ) (4 )
Amortization of discount, premium and changes in accrued interest from marketable securities 4 - -
Accrued severance pay, net (1 ) 10 58
Net cash provided by operating activities $ 3,461 $ (688 ) $ (5,755 )

CASH FLOWS FROM INVESTING ACTIVITIES:

Purchase of property and equipment $ (179 ) $ (426 ) $ (962 )
Investment in short-term deposits (31,599 ) - -
Proceeds from short-term deposits - 400 898
Proceeds from sale of property and equipment - 28 29
Investment in long-term deposits (690 ) - (14 )
Repayment of long-term restricted deposit 4 2 13
Purchase of available for sale marketable securities (516 ) - -
Net cash provided by (used in) investing activities $ (32,980 ) $ 4 $ (36 )

	Six months ended December 31,						Year ended June 30,
	2011			2010			2011
	Unaudited			Unaudited			Audited
CASH FLOWS FROM FINANCING ACTIVITIES:
Issuance of common stock and warrants, net of issuance costs	$	-		$	5,015		$	43,400
Exercise of warrants and options		400			17			3,661
Repayment of long-term loan		-			(24	)		(24	)
Net cash provided by financing activities	$	400		$	5,008		$	47,037

Increase (decrease) in cash and cash equivalents		(36,157	)		3,156			41,246
Cash and cash equivalents at the beginning of the period		42,829			1,583			1,583
Cash and cash equivalents at the end of the period	$	6,672		$	4,739		$	42,829

(a) Supplemental disclosure of cash flow activities:
Cash paid during the period for:
Taxes paid due to non-deductible expenses	$	10	$	7	$	11

(b) Supplemental disclosure of non-cash activities:
Increase (decrease) in fair value of marketable securities	$	(134	)	$	-	$	-
Purchase of property and equipment in credit	$	121		$	73	$	123
Issuance of shares in consideration of accounts receivable	$	-		$	243	$	-
Issuance of shares in consideration of leasehold improvements	$	1,245		$	-	$	-

The accompanying notes are an integral part of the consolidated financial statements.

~~F - 7~~

~~PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY~~

~~CONSOLIDATED STATEMENTS OF CASH FLOWS~~

~~U.S. Dollars in thousands~~

Three months ended
September 30,

Year ended
June 30,

2011 2010 2011
Unaudited Unaudited Audited
CASH FLOWS FROM FINANCING ACTIVITIES:
Issuance of common stock and warrants, net of issuance costs $ - $ 252 $ 43,400
Exercise of warrants and options 323 - 3,661
Repayment of long-term loan - (24 ) (24 )
Net cash provided by financing activities $ 323 $ 228 $ 47,037

Increase (decrease) in cash and cash equivalents (29,196 ) (456 ) 41,246
Cash and cash equivalents at the beginning of the period 42,829 1,583 1,583
Cash and cash equivalents at the end of the period $ 13,633 $ 1,127 $ 42,829

(a) Supplemental disclosure of cash flow activities:
Cash paid during the period for:
Taxes paid due to non-deductible expenses $ 8 $ 5 $ 11

(b) Supplemental disclosure of non-cash activities:
Increase in fair value of marketable securities $ 1 $ - $ -
Purchase of property and equipment in credit $ 109 $ 73 $ 123

~~The accompanying notes are an integral part of the consolidated financial statements.~~

F - 8

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL ~~STA~~TESTATEMENTS~~MENTS~~

U.S. Dollars in thousands (except per share amounts)

NOTE 1:-GENERAL

Pluristem Therapeutics Inc., a Nevada corporation, was incorporated on May 11, 2001. Pluristem Therapeutics Inc. has a wholly owned subsidiary, Pluristem Ltd. (the “Subsidiary”), which is incorporated under the laws of the State of Israel. Pluristem Therapeutics Inc. and the Subsidiary are referred to as the “Company”.

The Company is a bio-therapeutic company developing standardized cell therapy products from human placenta for the treatment of multiple disorders. The Company ~~have~~has sustained operating losses and expects such losses to continue in the foreseeable future. The Company's accumulated losses aggregated to ~~$55,446~~$57,438 through ~~September 30,~~December 31, 2011 and the Company incurred a net loss of ~~$4,493~~$6,485 for the ~~three~~six months ended ~~September 30,~~December 31, 2011. There is no assurance that profitable operations, if ever achieved, could be sustained on a continuing basis.

The Company plans to continue to finance its operations with sales of equity securities, entering into licensing technology agreements such as the United Therapeutics Corporation (“United Therapeutics”), agreement, and from grants to support its R&D activity. In the longer term, the Company plans to finance its operations from revenues from sales of products.

The Company was in the development stage from its inception until July 2011 (see 2a below).

Since December 10, 2007, the Company’s shares of common stock have been traded on the NASDAQ Capital Market under the symbol PSTI. On May 7, 2007, the Company’s shares also began trading on Europe’s Frankfurt Stock Exchange under the symbol ~~PJT.~~PJTA.

On December 19, 2010, the Company’s shares began trading on the Tel-Aviv Stock Exchange under the symbol “PLTR”.

Licence Agreement:

On June 19, 2011, the Company entered into an exclusive license agreement, or the License Agreement, with United Therapeutics, for the use of its PLX cells to develop and commercialize a cell-based product for the treatment of Pulmonary Hypertension ("PAH"). The License Agreement provides that United Therapeutics will receive exclusive worldwide license rights for the development and commercialization of the Company's PLX cell-based product to treat PAH. The License Agreement provides for the following consideration payable to the Company: (i) an upfront payment of $7,000 paid in August 2011, which includes a $5,000 non-refundable upfront payment and $2,000 refundable advance payment on the development ; (ii) up to $37,500 upon reaching certain regulatory milestones with respect to the development of a product to treat PAH; (iii) reimbursement of up to $10,000 of certain of the Company expenses if the Company ~~establish~~establishes a manufacturing facility in North America upon meeting certain milestones; (iv) reimbursement of certain costs in connection with the development of the product; and (v) following commercialization of the product, royalties and the purchase of commercial supplies of the developed product from the Company at a specified margin over the ~~Company~~Company’s cost.

On August 2, 2011, the ~~agreement~~License Agreement became effective following the consent of the Office of the Chief Scientist of Israel.

F - 9

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. Dollars in thousands (except per share amounts)

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES

The accompanying unaudited interim financial statements of Pluristem Therapeutics Inc. have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission and should be read in conjunction with the audited financial statements and notes thereto contained in Pluristem’s latest Annual Report on Form 10-K filed with the SEC. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim periods presented have been reflected herein. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements that would substantially duplicate the disclosure contained in the audited financial statements for the most recent fiscal year as reported in the Form 10-K have been omitted. Commencing July 2011, the Company ceased to consider itself a development stage company.

Short-term deposits

The Company considers all highly liquid investments that are convertible to cash with original maturities of more than three months and less than one year as short-term deposits.

Marketable Securities

The Company accounts for its investments in marketable securities in accordance with ASC 320 “Investments - Debt and Equity Securities”. The Company determines the classification of marketable securities at the time of purchase and reevaluates such designations as of each balance sheet date. The Company classifies all of its marketable securities as available-for-sale. Available-for-sale marketable securities are carried at fair value, with the unrealized gain and loss reported as a separate component of shareholders' equity, accumulated other comprehensive income (loss).

Realized gain and loss on sales of marketable securities are included in the Company's statements of operations and are derived using the specific identification basis for determining the cost of marketable securities. The amortized cost of available for sale marketable securities is adjusted for amortization of premiums and accretion of discount to maturity. Such amortization, together with interest on available for sale marketable securities, is included in the financial income (expenses), net.

The Company recognizes an impairment charge when a decline in the fair value of its available-for-sale marketable securities below the cost basis is judged to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the length of time the investment has been in a loss position, the extent to which the fair value has been less than the Company's cost basis, the investment’s financial condition and the near-term prospects of the issuer. The Company adopted FASB ASC 320-10-65 effective January 1, 2009, which requires an other-than-temporary impairment for debt securities to be separated into (a) the amount representing the credit loss and (b) the amount related to all other factors (provided that the Company does not intend to sell the security and it is not more likely than not that it will be required to sell it before recovery). The Company classifies its marketable securities as available-for-sale and marks them to market with changes to other comprehensive income until realization or occurrence of other than temporary impairment loss.

Revenue Recognition from the license Agreement with United Therapeutics

The Company recognizes revenue pursuant to the License Agreement with United Therapeutics in accordance with ASC 625-25 "Revenue Recognition, Multiple-Element Arrangements" ~~.Pursuant~~. Pursuant to this guidance, the Company ~~determines~~determined that its arrangement with United Therapeutics involves multiple revenue-generating deliverables that should be accounted for as a separate units of accounting for revenue recognition purposes.

The Company received an up-front, non-refundable license payment of $5,000. Additional payments ~~totalling~~totaling $37,500 are subject to the Company's meeting certain milestones.

F - 10

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. Dollars in thousands (except per share amounts)

~~NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES (CONT.)~~

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES (CONT.)

Revenue Recognition from the license Agreement with United Therapeutics (cont.)

The non-refundable upfront license fee of $5,000 is deferred and recognized over the related performance period in accordance with SAB 104 "Revenue Recognition". The Company estimated the performance period of the development of approximately 5.5 years. The license fee will be recognized on a straight line basis as revenue over the estimated development period, resulting in revenue of ~~$154~~$385 for the ~~three~~six months ended ~~September 30,~~December 31, 2011.

The additional milestones payments will be recognized upon the achievement of the specific milestone, in accordance with EITF Issue No. 08-9, “Milestone Method of Revenue Recognition".

The Company also received a refundable, advance payment on the development, of $2,000 that will be deductible against development expenses as it accrued. This upfront payment received and not recognized as revenues is included in the balance sheet as advanced payment. All expenses related to the development, on cost basis, shall be repaid to the Company by United Therapeutics. The Company ~~will deduct~~is deducting the payments from the R&D expenses in accordance with ASC 730 "Research and Development".

During the six month period ended December 31, 2011, the Company deducted an amount of approximately $74.

~~Impact of recently issued accounting standards:~~

On June 16, 2011, the FASB "The Financial Accounting Standards Board (FASB)" issued ASU No. 2011-05, Presentation of Comprehensive Income. This standard eliminates the current option to report other comprehensive income and its components in the statement of changes in shareholders’ equity and provides for either a single continuous statement or two separate statements. Both options require companies to present the components of net income and total net income, the components of other comprehensive income along with a total for other comprehensive income. Companies are also required to present reclassification adjustments for items that are reclassified from other comprehensive income to net income within these statements. This standard will be applied retrospectively for fiscal years beginning after December 15, 2011 with early adoption permitted. The disclosure requirements of this standard will not have a material effect on the Company’s results of operations or financial position as the amendment impacts presentation only.

For additional description of recent accounting pronouncements relevant to the Company, please refer to “Recently issued accounting standards” section included in Note 2 to the Company's Annual Report on Form 10-K for the year ended June 30, 2011.

Fair value of financial instruments:

The carrying amounts of the Company's financial instruments, including cash and cash equivalents, available-for-sale marketable securities, short-term deposits, trade payable and other accounts payable and accrued liabilities, approximate fair value because of their generally short term maturities.

The Company accounts for certain assets and liabilities at fair value under FASB ASC 820, “Fair Value Measurements and Disclosures.” Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. As a basis for considering such assumptions, FASB ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:

~~F - 11~~

~~PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS~~

~~U.S. Dollars in thousands (except per share amounts)~~

~~NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES (CONT.)~~

~~Fair value of financial instruments (cont.):~~

Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets;

Level 2 - Includes other inputs that are directly or indirectly observable in the marketplace, other than quoted prices included in Level 1, such as quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets with insufficient volume or infrequent transactions, or other inputs that are observable (model-derived valuations in which significant inputs are observable), or can be derived principally from or corroborated by observable market data; and

Level 3 - Unobservable inputs which are supported by little or no market activity.

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company categorized each of its fair value measurements in one of these three levels of hierarchy.

Impact of recently issued accounting standards:

On June 16, 2011, the Financial Accounting Standards Board issued ASU No. 2011-05, “Presentation of Comprehensive Income”.

F - 11

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. Dollars in thousands (except per share amounts)

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES (CONT.)

Impact of recently issued accounting standards: (cont.)

This standard eliminates the current option to report other comprehensive income and its components in the statement of changes in shareholders’ equity and provides for either a single continuous statement or two separate statements.

Both options require companies to present the components of net income and total net income, the components of other comprehensive income along with a total for other comprehensive income. Companies are also required to present reclassification adjustments for items that are reclassified from other comprehensive income to net income within these statements. This standard will be applied retrospectively for fiscal years beginning after December 15, 2011 with early adoption permitted. The disclosure requirements of this standard will not have a material effect on the Company’s results of operations or financial position as the amendment impacts presentation only.

For additional description of recent accounting pronouncements relevant to the Company, please refer to “Recently issued accounting standards” included in Note 2 in the financial statements included in the Company's Annual Report on Form 10-K for the year ended June 30, 2011.

NOTE 3:- MARKETABLE SECURITIES

As of ~~September 30,~~December 31, 2011, all of the Company’s marketable securities were classified as available-for-sale.

September 30, 2011 June 30,2011
Amortized cost
Gross
unrealized
gain

Gross
unrealized
loss

Fair
value
Amortized cost
Gross
unrealized
gain

Gross
unrealized
loss

Fair
value

Available-for-sale - matures within one year:
Corporate debentures – fixed interest rate 42 1 - 43 - - - -
Available-for-sale - matures after one year through five years:
Corporate debentures – fixed interest rate 384 3 (2 ) 385 - - - -
Available-for-sale - matures after five year through ten years:
Corporate debentures – fixed interest rate 86 - (1 ) 85 - - - -
512 4 (3 ) 513 - - - -

	December 31, 2011									June 30,2011
	Amortized cost		Gross unrealized gain		Gross unrealized loss			Fair value		Amortized cost		Gross unrealized gain		Gross unrealized loss		Fair value
Available-for-sale - matures within one year:
Equity Funds	$	1,108	$	21	$	(20	)	$	1,109	$	-	$	-	$	-	$	-
Corporate debentures – fixed interest rate		196		1		-			197		-		-		-		-
	$	1,304	$	22	$	(20	)	$	1,306	$	-	$	-	$	-	$	-
Available-for-sale - matures after one year through five years:
Government debentures – fixed interest rate		1,355		3		(43	)		1,315		-		-		-		-
Corporate debentures – fixed interest rate		879		-		(42	)		837		-		-		-		-
	$	2,234	$	3	$	(85	)	$	2,152	$	-	$	-	$	-	$	-
Available-for-sale - matures after five year through ten years:
Government debentures – fixed interest rate		545		-		(30	)		515		-		-		-		-
Corporate debentures – fixed interest rate		403		-		(24	)		379		-		-		-		-
	$	948	$	-	$	(54	)	$	894	$	-	$	-	$	-	$	-
	$	4,486	$	25	$	(159	)	$	4,352	$	-	$	-	$	-	$	-

F - 12

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. Dollars in thousands (except per share amounts)

NOTE 4:- FAIR VALUE OF FINANCIAL INSTRUMENTS

In accordance with FASB ASC 820, “Fair Value Measurements and Disclosures,” the Company measures its available-for-sale marketable securities contracts at fair value.

	September 30, 2011							June 30, 2011						December 31, 2011							June 30, 2011
	Level 1		Level 2			Level 3		Level 1		Level 2		Level 3		Level 1		Level 2			Level 3		Level 1		Level 2		Level 3
Short term deposits		31,658		-			-		-		-		-	$	30,491	$	-		$	-	$	-	$	-	$	-
Corporate bonds		513		-			-		-		-		-		4,352		-			-		-		-		-
Foreign currency cash flow hedges		-		(90	)		-		-		7		-		-		(171	)		-		-		7		-
Total		32,171		(90	)		-		-		7		-	$	34,843	$	(171	)	$	-	$	-	$	7	$	-

~~NOTE 5: - COMMITMENTS AND CONTINGENCIES~~

NOTE 5: - COMMITMENTS AND CONTINGENCIES

Commitments and contingencies that occurred during the ~~three~~six months ended ~~September 30,~~December 31, 2011 includes the following:

An amount of ~~$686~~$1,157 was pledged by the Company to secure ~~the~~its hedging transactions, credit line and bank guarantees.

In July 2011, the Company has entered into an agreement with MTM – Scientific Industries Center Haifa Ltd., for the leasing and construction of a new ~~state-of-the-art~~ GMP manufacturing facility. The new facility will be located near the Company’s headquarters and existing facilities in MATAM Park, Haifa, Israel. According to the agreement, the lease of the new facility is expected to commence in January 2012 for a period of approximately 5 years with an option to extend the lease for an additional 5 ~~years~~year period.

The Company has issued an additional bank guarantee in favor of MTM in the amount of approximately $263.

In December 9, 2011, the Company has entered into an agreement with Aseptic Technologies for the rental of a machine. The Company has issued an additional bank guarantee in favor Aseptic Technologies in amount of approximately $81.

NOTE 6: - SHARE CAPITAL AND STOCK OPTIONS

The Company's authorized common stock consists of 100,000,000 shares with a par value of $0.00001 per share. All shares have equal voting rights and are entitled to one vote per share in all matters to be voted upon by stockholders. The shares have no pre-emptive, subscription, conversion or redemption rights and may be issued only as fully paid and non-assessable shares. Holders of the common stock are entitled to equal ratable rights to dividends and distributions with respect to the common stock, as may be declared by the Board of Directors out of funds legally available.

The Company's authorized preferred stock consists of 10,000,000 shares of preferred stock, par value $0.00001 per share, with series, rights, preferences, privileges and restrictions as may be designated from time to time by the Company’s Board of Directors. No shares of preferred stock have been ~~currently~~ issued.

In ~~July-September~~July till December 2011, a total of ~~60,000~~156,122 warrants were exercised via a “cashless” ~~manner,~~exercise, resulting in the issuance of ~~23,514~~77,166 shares of common stock to investors of the Company. In addition ~~175,200~~206,100 warrants were exercised and resulted in the issuance of ~~175,200~~206,100 shares of common stock by investors of the Company. The aggregate cash consideration received was ~~$315.~~$371.

F - 13

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. Dollars in thousands (except per share amounts)

NOTE 6: - SHARE CAPITAL AND STOCK OPTIONS (CONT.)

~~The following table summarizes~~On October 26, 2011, the ~~issuance~~Company issued 500,000 shares as an advance payment to Biopharmax as part of ~~shares of common stock to~~ the ~~Company’s investor relations consultants as compensation~~agreement for ~~their services since July 1, 2010.~~building the new Company facility.

Period of service
Number of shares issued Fair market value of the shares issued at the issuance date
Expenses in the
statements of operations
for the Year ended June 30

2011 2012
July 2010 – March 2011 90,000 155 155 -
Total 90,000 $ 155 $ 155 $ -

~~The issuance of shares to the consultants was in some cases in addition to cash compensation the consultants were entitled to.~~

F - 14

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. Dollars in thousands (except per share amounts)

NOTE 6: - SHARE CAPITAL AND STOCK OPTIONS (CONT.)

Options, warrants, restricted stock and restricted stock units to employees, directors and consultants:

The Company has approved two incentive option plans from 2003 and from 2005 (the “2003 Plan" and the “2005 Plan”, and collectively, the “Plans”). Under these Plans, options, restricted stock and restricted stock units (the “Awards”) may be granted to the Company’s officers, directors, employees and consultants. Any Awards that are cancelled or forfeited before expiration become available for future grants.

As of ~~September 30,~~December 31, 2011, the number of shares of common stock authorized for issuance under the 2005 Plan amounted to ~~10,187,764. 2,346,716~~10,505,995. 1,131,281 shares are still available for future grant under the 2005 Plan as of ~~September 30,~~December 31, 2011. Under the 2003 Plan 20,500 options are authorized for issuance, and ~~13,040~~15,296 options are still available for future grant as of ~~September 30,~~December 31, 2011.

a. Options to employees and directors:

The Company accounted for its options to employees and directors under the fair value method in accordance with ASC 718, "Compensation — Stock Compensation". A summary of the Company’s share option activity for options granted to employees and directors under the Plans is as follows:

	Three months ended September 30, 2011									Six months ended December 31, 2011
	Number			Weighted Average Exercise Price		Weighted Average Remaining Contractual Terms (in years)		Aggregate Intrinsic Value Price		Number			Weighted Average Exercise Price		Weighted Average Remaining Contractual Terms (in years)		Aggregate Intrinsic Value Price
Options outstanding at beginning of period		2,200,616		$	3.84						2,200,616		$	3.84
Options exercised		(7,500	)		0.62						(18,000	)		0.62
Options forfeited		(9,384	)		3.54						(64,046	)		3.65
Options outstanding at end of the period		2,183,732		$	3.86		5.51	$	824		2,118,570		$	3.88		5.39	$	981
Options exercisable at the end of the period		2,183,732		$	3.86		5.51	$	824		2,118,570		$	3.88		5.39	$	981
Options vested and expected to vest		2,183,732		$	3.86		5.51	$	824		2,118,570		$	3.88		5.39	$	981

Intrinsic value of exercisable options (the difference between the Company’s closing stock price on the last trading day in the period and the exercise price, multiplied by the number of in-the-money options) represents the amount that would have been received by the employees and directors option holders had all option holders exercised their options on ~~September 30,~~December 31, 2011. This amount changes based on the fair market value of the Company’s common stock.

Compensation expenses related to options granted to employees and directors were recorded as follows:

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. Dollars in thousands (except per share amounts)

NOTE 6: - SHARE CAPITAL AND STOCK OPTIONS (CONT.)

d.e.

Options, warrants, restricted stock and restricted stock units to employees, directors and consultants (cont.):

b. Options and warrants to non-employees:

On December 21, 2011, the Company's Compensation Committee approved a grant of a total of 12,000 options to the Company's consultants

A summary of the Company’s activity related to options and warrants to consultants is as follows:

Weighted Average

Exercise Price

Weighted Average

Remaining Contractual

Terms (in years)

Aggregate

Intrinsic

Value Price

Weighted Average Exercise Price

Weighted Average Remaining Contractual Terms (in years)

Aggregate Intrinsic Value Price

~~Compensation expenses related to options and warrants granted to consultants were recorded as follows:~~

Compensation expenses related to options and warrants granted to consultants were recorded as follows:

Future expenses related to options and warrants granted to consultants for an average time of almost two years is ~~$23.~~$40.

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. Dollars in thousands (except per share amounts)

NOTE 6: - SHARE CAPITAL AND STOCK OPTIONS (CONT.)

~~NOTE 6: - SHARE CAPITAL AND STOCK OPTIONS~~ ~~(CONT.)~~

d.e.

Options, warrants, restricted stock and restricted stock units to employees, directors and consultants (cont.):

c. Restricted stock and restricted stock units to employees and directors:

On December 21, 2011, the Company's Compensation Committee approved a grant of a total of 1,547,250 restricted stock units to the Company's employees and directors.

The following table summarizes the activities for unvested restricted stock units and restricted stock granted to employees and directors for the ~~three~~six months ended ~~September 30,~~December 31, 2011:

	Number
Unvested at the beginning of period		2,138,955
Granted		1,573,638
Forfeited		(10,623	)
Vested		(~~305,845~~814,160	)
Unvested at the end of the period		~~1,822,487~~2,887,810
Expected to vest after ~~September 30,~~December 31, 2011		~~1,784,207~~2,838,670

Compensation expenses related to restricted stock and restricted stock units granted to employees and directors were recorded as follows:

	Three months ended September 30,				Six months ended December 31,				Three months ended December 31,
	2011		2010		2011		2010		2011		2010
Research and development expenses	$	253	$	135	$	483	$	417	$	230	$	282
General and administrative expenses		679		233		1,290		821		612		588
	$	932	$	368	$	1,773	$	1,238	$	842	$	870

~~Future expenses related to restricted stock and restricted stock units granted to employees and directors for an average time of almost two years is $1,826.~~

Future expenses related to restricted stock and restricted stock units granted to employees and directors for an average time of almost two years is $4,975.

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. Dollars in thousands (except per share amounts)

NOTE 6: - SHARE CAPITAL AND STOCK OPTIONS (CONT.)

d.e.

Options, warrants, restricted stock and restricted stock units to employees, directors and consultants (cont.):

~~d. Restricted stock and restricted stock units to consultants:~~

d. Restricted stock and restricted stock units to consultants:

During the six months ended December 31, 2011, the Company granted to several consultants and service providers restricted stock.

The following table summarizes the activities for unvested restricted stock units and restricted stock granted to consultants for the ~~three~~six months ended ~~September 30,~~December 31, 2011:

	Number
Unvested at the beginning of period		149,998

Granted		433

Vested		(~~24,999~~53,431	)
Unvested at the end of the period		~~124,999~~97,000
Expected to vest after ~~September 30,~~December 31, 2011		~~124,999~~97,000

Compensation expenses related to restricted stock and restricted stock units granted to consultants were recorded as follows:

	Three months ended September 30,				Six months ended December 31,				Three months ended December 31,
	2011		2010		2011		2010		2011		2010
Research and development expenses	$	92	$	24	$	112	$	74	$	53	$	50
General and administrative expenses		-		53		1		127		1		74
	$	92	$	77	$	113	$	201	$	54	$	124

Future expenses related to restricted stock and restricted stock units granted to consultants for an average time of almost two years is ~~$90.~~$58.

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. Dollars in thousands (except per share amounts)

NOTE 6: - SHARE CAPITAL AND STOCK OPTIONS (CONT.)

f. e. Summary of warrants and options:

A summary of all the warrants and options outstanding as of ~~September 30,~~December 31, 2011 is presented in this table:

Exercise Price per Share

Options and Warrants for Common Stock

Options and Warrants Exercisable

Weighted Average Remaining Contractual Terms(in years)

Exercise Price per Share

Options and Warrants for Common Stock

Options and Warrants Exercisable

Weighted Average Remaining Contractual Terms(in years)

This summary does not include ~~1,947,487~~2,984,810 restricted stock units that are not vested as of ~~September 30,~~December 31, 2011.

~~PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS~~

~~U.S. Dollars in thousands (except per share amounts)~~

~~NOTE 7: - SUBSEQUENT EVENTS~~

On October 30, 2011, the Company's wholly owned Israeli subsidiary, Pluristem Ltd. (“Pluristem”), entered into an agreement for the design and construction of a manufacturing facility of bio-pharmaceutical products (the “Agreement”) with Biopharmax Group (1996) Ltd., a company specializing in the design and construction of biotechnological and pharmaceutical facilities (the “Contractor”). Under the terms of the Agreement, the Contractor is required to design and construct Pluristem’s new manufacturing facility, in a space to be leased as of January 2012, as a turn key project (the “Project”) that will meet the requirements of the U.S., Canadian, Israeli and European regulatory authorities and current Good Manufacturing Practices (cGMP). The Project is planned to be completed in the fourth calendar quarter of 2012. The Contractor is required to pay certain penalties for not meeting the time schedule agreed between the parties.

Pursuant to the terms of the Agreement, the Contractor is eligible to receive aggregate consideration of NIS 22,800 (approximately $6,247 based on current exchange ratio of $1=NIS3.65) plus value added tax. Pluristem has the option to pay a certain portion of the said consideration in up to 2,000,000 shares of Common Stock of the Company (the “Shares”). The net cash consideration received by Contractor from the immediate sale of the Shares shall be deducted from the aggregate consideration owed to the Contractor; or in the event that Contractor elects to hold the Shares rather than selling them, the value of the Shares based on the closing price of the Company's shares of common stock on Nasdaq on the date in which the Shares have been issued to Contractor shall be deducted from the aggregate consideration owed to the Contractor. Pursuant to the terms of the Agreement, the Contractor shall provide Pluristem certain guarantees in connection with the performance of the Contractor's obligations under the Agreement.

Pluristem may terminate the Agreement at any time by a written notice to the Contractor. In case of termination by Pluristem for convenience, Pluristem shall be required to pay penalty of $250 in addition to the payment for the services provided by the Contractor prior to the termination date.

In early November 2011, a Memorandum of Law for Socioeconomic Change (Legislative Amendments) (Taxes), 2011 (the “Memorandum of Law"), was published. The Memorandum of Law proposes, among others, to cancel, effective from 2012, the scheduled progressive reduction in the corporate tax rate. The Memorandum of Law also proposes to raise the corporate tax rate to 25% in 2012. In view of the proposed increase in the corporate tax rate to 25% in 2012, the real capital gains tax rate and the real betterment tax rate will also be increased.

~~The Company estimates that the approval by the Israeli Parliament of the Memorandum of Law as described above is not expected to have a material effect on the financial statements of Pluristem Ltd.~~

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Forward - Looking Statements

This quarterly report on Form 10-Q contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws, and is subject to the safe-harbor created by such Act and laws. Forward-looking statements may include statements regarding our goals, beliefs, strategies, objectives, plans, including product and technology developments, future financial conditions, results or projections or current expectations. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential” or “continue,” the negative of such terms, or other comparable terminology. These statements are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause actual results to be materially different from those contemplated by the forward-looking statements. Such forward-looking statements appear in this Item 2 – “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and include, but are not limited to, statements regarding the following: the expected development and potential benefits from our products in treating various medical conditions, the safety and efficacy of our PLX-PAD product as well as the extent to which it is tolerated, our plans, intentions or expectations regarding clinical studies and publication of results of such studies, our expectations regarding our short and long-term capital requirements and sufficiency of our capital resources, our plans to raise additional funding, including non-dilutive funding and governmental grants, the success of our plans to develop in house manufacturing capacity of clinical grade PLX cells in commercial quantities, the expansion of our relationships with research and clinical institutions as well as collaboration with other companies and information with respect to any other plans and strategies for our business. Our business and operations are subject to substantial risks, which increase the uncertainty inherent in the forward-looking statements contained in this report. Except as required by law, we undertake no obligation to release publicly the result of any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Further information on potential factors that could affect our business is described under the heading “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended June 30, 2011. Readers are also urged to carefully review and consider the various disclosures we have made in that report.

As used in this quarterly report, the terms “we”, “us”, “our”, the “company” and “Pluristem” mean Pluristem Therapeutics Inc. and our wholly owned subsidiary, Pluristem Ltd., unless otherwise indicated or as otherwise required by the context.

We are a leading bio-therapeutic company developing standardized cell therapy products for the treatment of life threatening diseases. We are developing a pipeline of products, stored ready-to-use, derived from human placenta, a non-controversial, non-embryonic, adult cell source. Placental-derived adherent stromal cells are grown in the Company's proprietary PluriX™ three-dimensional process that allows cells to grow in a more natural environment and enable us to produce large quantities of clinical grade cells. We refer to the cells that are grown in the PluriX™ as our PLacental eXpanded cells, or PLX cells. We are expanding our in-house manufacturing capacity so that we will be able to grow large scale quantities of our cells efficiently and without reliance on outside vendors.

Our strategy is to develop and manufacture cell therapy products for the treatment of multiple disorders via several routes of administration. We plan to execute this strategy both independently, using our own personnel and via relationships with research and clinical institutions, or in collaboration with other companies, such as United Therapeutics Corporation, or United. We plan to have in-house manufacturing capacity of clinical grade PLX cells in commercial quantities and to control all of our proprietary manufacturing processes in order to assist in executing this strategy.

We believe that intramuscular administration, which means that the cells are administrated locally to the muscle and not systemically, may be ~~suited~~suitable for a number of different clinical indications. Such indications include peripheral artery disease, or PAD, critical limb ischemia, or CLI, intermittent claudication, muscle injuries, thromboangiitis obliterans, or Buerger's disease, neuropathic pain, wound healing and orthopedic injuries. In addition, we have reported pre-clinical studies utilizing successfully our proprietary PLX cells when administered systemically via the intravenous route in treating multiple sclerosis, ischemic stroke, inflammatory bowel disease and radiation exposure. Under our exclusive license agreement, or the United Agreement, with United, we plan to participate in the development and commercialization of a PLX cell-based product for the treatment of Pulmonary Arterial Hypertension, or PAH.

Our first product in development, called PLX-PAD, is intended to improve the quality of life of millions of people suffering from PAD. In November 2011, following completion of twelve month clinical follow-ups using our PLX cells in CLI, the end-stage of PAD, we announced that the data collected from our two open-label, dose-escalation, Phase I clinical trials conducted in the United States and Germany demonstrated a safe immunologic profile at all dosage levels and found PLX-PAD to be potentially effective in treating patients suffering from CLI. During the Phase I clinical trials we have collected information regarding the Amputation Free Survival, ~~(AFS)~~or AFS, rate and since our Phase I clinical trials did not include control groups, we compared the data with another published CLI trial's control data, ~~(Historical Data).~~or Historical Data. The data showed that from a total of twenty-seven patients, four treatment failures, ~~(Event)~~or Event, occurred during the observation period of twelve months, which resulted in an AFS rate of 85.2%, as opposed to Historical Data of 66.8% for the same time period. This corresponded to an Event rate of 14.8%, as opposed to Historical Data showing a 33.2% Event rate.

In June 2011, we entered into an exclusive license agreement, or the License Agreement, with United, for the use of our PLX cells to develop and commercialize a cell-based product for the treatment of PAH. The License Agreement provides that United will receive exclusive worldwide license rights for the development and commercialization of our PLX cell-based product to treat PAH. The License Agreement provides for the following consideration payable to us: (i) $7 million paid to us in August 2011; (ii) up to $37.5 million upon reaching certain regulatory milestones with respect to the development of a product to treat PAH; (iii) reimbursement of up to $10 million of certain of our expenses if we establish a manufacturing facility in North America upon meeting certain milestones; (iv) reimbursement of certain costs in connection with the development of the product; and (v) following commercialization of the product, royalties and the purchase of commercial supplies of the developed product from us at a specified margin over our cost.

In July 2011, we entered into an agreement with MTM – Scientific Industries Center Haifa Ltd. for the lease and construction of a new state-of-the-art GMP manufacturing facility. The new facility will be located near our headquarters and existing facilities in MATAM Park, Haifa, Israel. The lease of the new facility is expected to commence in January 2012 for a period of approximately five years with an option to extend the lease for an additional 5 years.

In August 2011, the U.S. Food and Drug Administration granted our PLX cells orphan status designation for the treatment of Buerger's disease. A concurrent application in Europe at the European Medicine Agencys’s Committee for Orphan Medicinal Products is pending

In September 2011, we announced that animal studies we have conducted suggest that our PLX cells may be effective in treating life threatening hematopoietic complications associated with Acute Radiation Syndrome.

In October 2011, we entered into an agreement for the design and construction of a manufacturing facility of bio-pharmaceutical products, or the Construction Agreement, with Biopharmax Group (1996) Ltd., a company specializing in the design and construction of biotechnological and pharmaceutical facilities, or the Contractor. Under the terms of the Construction Agreement, the Contractor is required to design and construct our new manufacturing facility, in a space to be leased as of January 2012, as a turn key project, or the Project, that will meet the requirements of the U.S., Canadian, Israeli and European regulatory authorities and current Good Manufacturing Practices (cGMP). The Project is planned to be completed in the fourth calendar quarter of 2012. The Contractor is required to pay certain penalties for not meeting the time schedule agreed between the parties.

Pursuant to the terms of the Construction Agreement, the Contractor is eligible to receive an aggregate consideration of NIS 22,800,000 (approximately $6,246,575 based on the then current exchange ratio of $1=NIS3.65) plus value added tax. We have the option to pay a certain portion of the said consideration in up to 2,000,000 shares of our common stock. We may terminate the Construction Agreement at any time by a written notice to the Contractor. In case of termination by us for convenience, we shall be required to pay the Contractor $250,000 in addition to the payment for the services provided by the Contractor prior to the termination date.

In January 2012, we announced that our wholly owned subsidiary, Pluristem Ltd., received approval for a NIS 9 million (approximately $2.4 million) grant from the Office of the Chief Scientist, or the OCS, within the Israeli Ministry of Industry, Trade and Labor. Once received, the grant will be used to cover R&D expenses for the period March 2011 to February 2012. This is the sixth grant received by us from the OCS and is subject to the same repayment restrictions of royalties as the prior grants.

Critical accounting policies

Our financial statements and accompanying notes are prepared in accordance with U.S. GAAP. Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. These estimates and assumptions are affected by management's application of accounting policies. We believe that understanding the basis and nature of the estimates and assumptions involved with the following aspects of our consolidated financial statements is critical to an understanding of our ~~financials~~financial statements.

We recognize revenue pursuant to the ~~License~~United Agreement ~~with United~~ in accordance with ASC 625-25 "Revenue Recognition, Multiple-Element Arrangements". Pursuant to this guidance, we determined that our arrangement with United involves multiple revenue-generating deliverables that should be accounted for as separate units of accounting for revenue recognition purposes.

We received an up-front, non-refundable license payment of $5,000,000. Additional payments totaling $37.5 million are subject to our Company's meeting certain milestones. The non-refundable upfront license fee of $5,000,000 is deferred and recognized over the related performance period in accordance with SAB 104 "Revenue Recognition". We estimated the performance period of the development of approximately 5.5 years. Future changes in estimates of the performance period may materially impact the timing and amounts of future revenue recognized. The license fee will be recognized on a straight line basis as revenue over the estimated development period, resulting in revenue of ~~$154,000~~$385,000 for the ~~three~~six months ended ~~September 30,~~December 31, 2011.

The additional milestones payments will be recognized upon the achievement of the specific milestone, in accordance with EITF Issue No. 08-9, “Milestone Method of Revenue Recognition".

We also received a refundable, advance payment on the development, of $2,000,000 that ~~will be~~is deductible against development expenses as it accrued. This upfront payment received and not recognized as revenues is included in the balance sheet as advanced payment. All expenses related to the development, on cost basis, shall be repaid to us by United. We ~~will deduct~~are deducting the payments from the R&D expenses in accordance with ASC 730 "Research and Development".

RESULTS OF OPERATIONS – SIX AND THREE MONTHS ENDED ~~SEPTEMBER 30,~~DECEMBER 31, 2011 COMPARED TO SIX AND THREE MONTHS ENDED ~~SEPTEMBER 30,~~DECEMBER 31, 2010.

Revenues for the six months ended December 31, 2011 in the amount of $385,000 are from the United Agreement. We did not generate revenues during the six months ended December 31, 2010.

Revenues for the three months ended ~~September 30,~~December 31, 2011 in the amount of ~~$154,000~~$231,000 are from the United ~~license agreement.~~Agreement. We did not generate revenues during the three months ended ~~September 30,~~December 31, 2010.

Research and Development

Research and development expenses, net of participation of the OCS and other grants, for the ~~three~~six months ended ~~September 30,~~December 31, 2011 increased by ~~185%~~52% from ~~$998,000~~$2,576,000 for the ~~three~~six months ended ~~September 30,~~December 31, 2010 to ~~$2,849,000.~~$3,923,000. This ~~significant~~ increase is attributed to the following reasons: The material increase in our in-house research and development activity, the increase in expenses related to the clinical and preclinical trials we are involved with and timing of approval of the OCS program. The material increase in research and development expenses resulted from increase in our salaries and lab materials expenses due to, among other things, hiring 2027 new employees since ~~September~~December 2010. In addition, the ~~OCS program~~research and development expenses for the ~~year beginning in March~~six months ended December 31, 2011 ~~has not yet been approved, resulting in a decrease in the~~are net of participation of the OCS ~~recorded~~for ten months in the ~~statements~~amount of ~~operation of $490,000,~~$1,896,000, compared to ~~the first quarter~~participation of the ~~previous year.~~OCS for the six months ended December 31, 2010 which are $1,111,000.

Research and development expenses, net of participation of the OCS and other grants, for the three months ended December 31, 2011 decreased by 32% from $1,578,000 for the three months ended December 31, 2010 to $1,074,000. This decrease is attributed to the following reasons: timing of approval of the OCS program, which resulted in $1,896,000 recognized in the three months ended December 31, 2011, compared with $608,000 recognized in the three months ended December 31, 2011, partially offset by an increase in our in-house research and development activity and the increase in expenses related to the clinical and preclinical trials we are involved with. The increase in research and development expenses resulted from an increase in our salaries due to, among other things, hiring 27 new employees since December 2010, and increases in laboratory materials expenses.

General and Administrative

General and administrative expenses for the ~~three~~six months ended ~~September 30,~~December 31, 2011 increased by ~~116%~~45% from ~~$756,000~~$2,002,000 for the ~~three~~six months ended ~~September 30,~~December 31, 2010 to ~~$1,637,000~~$2,912,000 mainly due to stock-based compensation expenses related to our employees and consultants which increased by approximately ~~$520,000,~~$595,000 and due to general and administrative costs related to the United ~~agreement~~Agreement such as bonuses that our officers and directors were entitled to as part of our bonus plan and legal fees involved.

General and administrative expenses for the three months ended December 31, 2011 increased by 2% from $1,246,000 for the three months ended December 31, 2010 to $1,275,000.

Financial Income, net

Financial income decreased from $68,000 for the six months ended December 31, 2010 to an expense of $35,000 for the six months ended December 31, 2011 due to exchange rate adjustments.

Financial income ~~of $65,000~~increased from $3,000 for the three months ended ~~September 30,~~December 31, 2010 to ~~expense of $161,000~~$126,000 for the three months ended ~~September 30, 2011. This decrease is attributed~~December 31, 2011 due to ~~exchange rate adjustments and costs of hedging transactions, partially offset by~~ an increase in interest income on bank deposits due to higher cash ~~balances.~~balances partially offset by exchange rate adjustments.

Net loss for the six and three months ended ~~September 30,~~December 31, 2011 was ~~$4,493,000,~~$6,485,000 and $1,992,000, respectively, as compared to net loss of ~~$1,689,000~~$4,510,000 and $2,821,000 for the six and three months ended ~~September 30, 2010.~~December 31, 2010, respectively. Net loss per share for the six and three months ended ~~September 30,~~December 31, 2011 was ~~$0.11,~~$0.15 and $0.05, respectively, as compared to ~~$0.08~~$0.20 and $0.11 for the six and three months ended ~~September 30,~~December 31, 2010.

For the periods ended ~~September 30,~~December 31, 2011 and ~~September 30,~~December 31, 2010, we had weighted average shares of common stock outstanding of ~~42,779,293~~43,225,017 and ~~21,012,208,~~22,954,736, respectively, that were used in the computations of net loss per share. The increase in weighted average common shares outstanding reflects mainly the shares of common stock issued in offerings that took place since ~~September~~December 2010 and shares issued as a result of exercise of warrants and options.

Liquidity and Capital Resources

As of ~~September 30,~~December 31, 2011, total current assets were ~~$46,363,000~~$43,843,000 and total current liabilities were ~~$5,045,000.~~$4,976,000. On ~~September 30,~~December 31, 2011, we had a working capital surplus of ~~$41,318,000, Stockholders'~~$38,867,000, stockholders' equity of ~~$40,294,000~~$40,352,000 and an accumulated deficit of ~~$55,446,000.~~$57,438,000. We finance our operations and plan to continue doing so from our existing cash, licensing agreements, funds from grants from the OCS and issuances of our securities.

Cash and cash equivalents as of ~~September 30,~~December 31, 2011 amounted to ~~$13,633,000.~~$6,672,000. This is a decrease of ~~$29,196,000~~$36,157,000 from the $42,829,000 reported as of June 30, 2011, which is mainly due ~~mainly,~~ to our investing in short-term and long-term bank deposits and in marketable securities, as further detailed below.

Cash balances decreased in the ~~three~~six months ended ~~September 30,~~December 31, 2011 for the reasons presented below.

Operating activities provided cash of ~~$3,461,000~~$174,000 in the ~~three~~six months ended ~~September 30,~~December 31, 2011. Cash provided by operating activities in the ~~three~~six months ended ~~September 30,~~December 31, 2011 primarily consisted of receiving the upfront payment related to the ~~License~~United Agreement ~~with United~~ in the amount of $7,000,000 ~~partially~~ offset by payments of salaries to our employees, and payments of fees to our consultants, subcontractors and professional services providers including costs of clinical studies.

Investing activities used cash of ~~$32,980,000~~$36,731,000 in the ~~three~~six months ended ~~September 30,~~December 31, 2011. The investing activities consisted primarily of investing in short-term and long-term bank deposits and in marketable securities. The investments were made in accordance with the policy set by our investment committee which aims to preserve our financial assets, maintain adequate liquidity and maximize return. Such policy further provides that we should hold the vast majority of our current assets in bank deposits and the remainder of our current assets is to be invested in government bonds and a combination of corporate bonds and relatively low risk stocks. As of today, the currency of our financial portfolio is mainly in USD and we use forward and options contracts in order to hedge our exposures to currencies other than the USD.

Financing activities generated cash of ~~$323,000~~$400,000 during the ~~three~~six months ended ~~September 30,~~December 31, 2011 from ~~exercise~~exercises of warrants by shareholders and ~~exercise~~exercises of options by employees and consultants.

During the ~~last quarter, 175,200~~past six months, 206,100 warrants were exercised in consideration for ~~$315,360,~~$370,980, and ~~60,000~~156,122 warrants were exercised on a cashless basis ~~for 23,514~~resulting in the net issuance of 77,166 shares of stock.

During the ~~three~~six months ended ~~September 30,~~December 31, 2011, we received approximately $16,000 from the OCS towards our research and development expenses. The OCS has supported our activity in the past five years. Recently we have received the OCS's approval of the sixth year grant in the amount of NIS 9 million (approximately $2.4 million) for participation in R&D expenses occurred during the period from March 1, 2011 and February 29, 2012. In ~~March 2011,~~January 2012, we filed an application for a ~~sixth~~seventh year ~~program for the period March 2011 until February 2012.~~program. There is no assurance that the OCS will approve a grant for the ~~sixth~~seventh year's R&D activity. The amount of the grant is also not certain.

We have accumulated a deficit of ~~$55,446,000~~$57,438,000 since our inception in May 2001. We do not expect to generate any revenues from sales of products in the next twelve months. Our products will likely not be ready for sale for at least three years, if at all. We expect to generate revenues, which in the short and medium terms will unlikely exceed our costs of operations, from the sale of licenses to use our technology or products, as we have in the ~~License Agreement we entered into in August 2011 with United.~~United Agreement. Our management believes that we may need to raise additional funds before we have cash flow from operations that can materially decrease our dependence on our existing cash and other liquidity resources. We are continually looking for sources of funding, including non-diluting sources such as the OCS grants. We have an effective shelf registration statement, which we may use in the future to raise additional funds.

We believe that the funds we have will be sufficient for operating until approximately the end of fiscal year of 2014.

Off Balance Sheet Arrangements

We have no off balance sheet arrangements.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures - We maintain a system of disclosure controls and procedures that are designed for the purposes of ensuring that information required to be disclosed in our SEC reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer (CEO) and our Chief Financial Officer (CFO), as appropriate to allow timely decisions regarding required disclosures.

As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our CEO and our CFO, of the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended. Based on that evaluation, our CEO and CFO concluded that our disclosure controls and procedures are effective.

Changes in Internal Control Over Financial Reporting - There has been no change in our internal control over financial reporting during the ~~first~~second quarter of fiscal 2012 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

In October 2011, we issued 433 shares to an investor relations consultant as partial consideration for services the consultant provides to the Company.

In October 2011, we issued 500,000 shares to our new facility contractor as partial consideration for services it is providing to the Company.

In December 2011 we issued 210,000 restricted stock units to two companies controlled by two of our directors in connection with compensation for such director’s services to us.

Item 5. Other Information.

On February 9, 2012, our Board of Director amended Section 4 of Article I of our By-laws to provide that the quorum in an adjourned meeting of the our shareholders shall be thirty three and one third percent (33 1/3%) of the Stock issued and outstanding and entitled to vote thereat instead of 10%. An amended and restated version of our By-laws is filed herewith as exhibit 3.1.

Item 6. Exhibits.

3.1	Amended and Restated By-laws.

10.1

Summary of ~~Lease~~Construction Agreement dated ~~January 22, 2003,~~October 30, 2011 by and between Pluristem Ltd. and MTM – Scientific Industries Center Haifa Ltd., as supplemented on December 11, 2005, June 12, 2007 and July 19, 2011 (incorporated by reference to Exhibit 10.2 of our annual report on Form 10-K filed on September 12, 2011).Biopharmax Group (1996) Ltd..

31.1*

Rule 13a-14(a) Certification of Chief Executive Officer.

31.2*

Rule 13a-14(a) Certification of Chief Financial Officer.

32.1**	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350.

32.2**	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350.

101 **	The following materials from our Quarterly Report on Form 10-Q for the quarter ended ~~September 30,~~December 31, 2011 formatted in XBRL (eXtensible Business Reporting Language): (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Operations, (iii) the Condensed Consolidated Statements of Cash Flows, (iv) the Statements of Changes in Stockholders (Deficiency) and (v) related notes to these financial statements, tagged as blocks of text.

**Furnished herewith.

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Zami Aberman, Chief Executive Officer

(Principal Executive Officer)

Date: ~~November~~February 9, ~~2011~~2012

Yaky Yanay, Chief Financial Officer

(Principal Financial Officer and Principal Accounting Officer)

Date: ~~November~~February 9, ~~2011~~2012

	Three months ended September 30, 2011									Six months ended December 31, 2011
	Number			Weighted Average Exercise Price		Weighted Average Remaining Contractual Terms (in years)		Aggregate Intrinsic Value Price		Number			Weighted Average Exercise Price		Weighted Average Remaining Contractual Terms (in years)		Aggregate Intrinsic Value Price
Options and warrants outstanding at beginning of period		425,000		$	3.65						425,000		$	3.65
Options and warrants granted											12,000			-
Options and warrants exercised		(5,000	)	$	0.62						(5,000	)		0.62
Options and warrants outstanding at end of the period		420,000		$	3.68		4.71	$	351		432,000		$	3.58		4.61	$	469

Options and warrants exercisable at the end of the period		373,000		$	4.01		4.88	$	300		411,000		$	3.77		4.35	$	417

Options and warrants vested and expected to vest		420,000		$	3.68		4.71	$	351		432,000		$	3.58		4.61	$	469

Warrants / Options	Exercise Price per Share		Options and Warrants for Common Stock		Options and Warrants Exercisable		Weighted Average Remaining Contractual Terms(in years)
Warrants:	$	1.00		2,059,972		2,059,972		2.17
	$	1.12		114,794		114,794		0.57
	$	1.20		12,500		12,500		1.05
	$	1.25 – 1.28		774,642		774,642		1.24
	$	1.40 - $ 1.50		1,806,707		1,806,707		3.08
	$	1.60		181,221		181,221		3.53
	$	1.80 - $ 1.96		3,752,345		3,752,345		2.71
	$	2.50		81,298		81,298		0.71
	$	4.20		5,060,000		5,060,000		4.84
	$	5.00		2,394,585		2,394,585		0.74
Total warrants				16,238,064		16,238,064

Options:	$	0.00		98,000		86,000		8.02
	$	0.62		482,112		482,112		7.12
	$	1.04-$ 1.45		145,006		110,006		3.87
	$	2.97		20,000		20,000		6.61
	$	3.50		982,938		982,938		4.92
	$	3.72 - $ 3.80		32,696		32,696		5.01
	$	4.00		42,500		42,500		5.05
	$	4.38 - $ 4.40		474,060		474,060		5.48
	$	6.80		36,250		36,250		6.12
	$	8.20		46,670		46,670		4.29
	$	20.00		142,500		142,500		4.73
Total options				2,502,732		2,455,732

Total warrants and options				18,740,796		18,693,796

Warrants / Options	Exercise Price per Share		Options and Warrants for Common Stock		Options and Warrants Exercisable		Weighted Average Remaining Contractual Terms(in years)

Warrants:	$	1.00		2,014,518		2,014,518		1.92
	$	1.12		114,794		114,794		0.32
	$	1.20		12,500		12,500		0.80
	$	1.25 – 1.28		762,642		762,642		0.99
	$	1.40 - $ 1.50		1,768,040		1,768,040		2.83
	$	1.60		181,221		181,221		3.28
	$	1.80 - $ 1.96		3,721,445		3,721,445		2.46
	$	2.50		81,298		81,298		0.46
	$	4.20		5,060,000		5,060,000		4.59
	$	5.00		2,394,585		2,394,585		0.49
Total warrants				16,111,043		16,111,043

Options:	$	0.00		110,000		89,000		8.01
	$	0.62		471,612		471,612		6.74
	$	1.04-$ 1.45		145,006		145,006		3.62
	$	2.97		20,000		20,000		6.36
	$	3.50		982,938		982,938		4.92
	$	3.72 - $ 3.80		31,550		31,550		4.94
	$	4.00		42,500		42,500		4.80
	$	4.38 - $ 4.40		464,304		464,304		5.34
	$	6.80		36,250		36,250		5.87
	$	8.20		46,670		46,670		4.04
	$	20.00		142,500		142,500		4.48
Total options				2,493,330		2,472,330

Total warrants and options				18,604,373		18,583,373

	Three months ended September 30,						Year ended June 30,
	2011			2010			2011
	Unaudited			Unaudited			Audited

Revenues	$	154		$	-		$	-

Research and development expenses		(2,868	)		(1,501	)		(8,311	)
Less participation by the Office of the Chief Scientist and other parties		19			503			1,682
Research and development expenses, net		(2,849	)		(998	)		(6,629	)
General and administrative expenses		(1,637	)		(756	)		(4,485	)

Operating loss		(4,332	)		(1,754	)		(11,114	)

Financial (expenses) income, net		(161	)		65			266

Net loss for the period	$	(4,493	)	$	(1,689	)	$	(10,848	)

Loss per share:
Basic and diluted net loss per share	$	(0.11	)	$	(0.08	)	$	(0.35	)

Weighted average number of shares used in computing basic and diluted net loss per share		42,779,293			21,012,208			31,198,825

(b) Supplemental disclosure of non-cash activities:
Increase in fair value of marketable securities	$	1	$	-	$	-
Purchase of property and equipment in credit	$	109	$	73	$	123

Period of service	Number of shares issued		Fair market value of the shares issued at the issuance date		Expenses in the statements of operations for the Year ended June 30
					2011		2012
July 2010 – March 2011	90,000		155		155		-
Total	90,000	$	155	$	155	$	-

	Three months ended September 30,				Six months ended December 31,				Three months ended December 31,
	2011		2010		2011		2010		2011		2010
Research and development expenses	$	-	$	4	$	-	$	3	$	-	$	1
General and administrative expenses		-		2		-		4		-		-
					$	-	$	7	$	-	$	1
	$	-	$	6